MAP3K7
Overview
MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7), also known as TAK1, is a serine/threonine kinase involved in TGF-beta, NF-kB, and MAPK signaling pathways. In prostate cancer, MAP3K7 undergoes recurrent focal deletion, particularly co-occurring with CHD1 loss, and defines an aggressive ETS-negative subtype.
Alterations observed in the corpus
- Recurrent focal deletion in the TCGA prostate adenocarcinoma cohort (n=333); co-deletion with CHD1 (5q15-q21) associated with aggressive ETS-negative disease PMID:26544944
Cancer types (linked)
- Prostate adenocarcinoma: recurrent focal deletion at 6q12-22; co-deletion with CHD1 marks aggressive ETS-negative subtype PMID:26544944
Co-occurrence and mutual exclusivity
- Co-deletion with CHD1 in prostate cancer; associated with ETS-negative, aggressive disease phenotype PMID:26544944
Therapeutic relevance
Open questions
Sources
This page was processed by crosslinker on 2026-05-14.